Brief Summary
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this new drug combination.
Brief Title
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Detailed Description
Total duration of the study for each participant is 9 to 10 months, consisting of a 1 month screening period, a 6 to 7 months treatment period, and a 30 day follow-up. All patients with stable disease or who have achieved partial or complete response and for whom dosing has been safe and reasonably well-tolerated may continue additional treatment cycles on the same regimen. Any patient whose imaging assessment shows disease progression after receiving at least two cycles of single agent weekly paclitaxel on ARM 1 may then be offered treatment with the combination of EP-100 plus paclitaxel in the same dose regimen as ARM 2.
Categories
Completion Date
Completion Date Type
Actual
Conditions
Ovarian Cancer Recurrent
Eligibility Criteria
Inclusion criteria:
* Adult patients with histologically confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.
* Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.
* Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.
* Karnofsky performance status \>/= 70%.
Exclusion criteria:
* Significant cardiac disease.
* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
* Pregnant or nursing women.
* Treatment with radiation therapy or investigational therapy within 4 weeks prior to Day 1. Had received chemotherapy prior to study entry equivalent to 3 to 5 half-lives of that chemotherapy agent or 4 weeks prior to study entry (whichever is shorter) with resolution of any side effects from that previous therapy (6 weeks for nitrosoureas or Mitomycin C.)
* Subjects with known central nervous system (CNS) metastases, either previously treated or current.
* Disease-free and off therapy for any other cancer within 5 years, except for adequately treated basal cell or squamous cell skin cancer or cervical intraepithelial neoplasia (CIN).
* Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1. o Had minor surgery (superficial incisions unlikely to obscure bleeding or infections) within 2 weeks prior to Day 1.
* Potentially life-threatening disease (hypercalcemia, spinal cord compression) whose disease may progress acutely during therapy.
* Unwilling or unable to comply with procedures required in this protocol.
* Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
* Susceptibility to histamine release.
* Chronic treatment with corticosteroids.
* Baseline QTc exceeding 450 msec (by Bazett's formula) and/or patients receiving class 1A or class III antiarrythmic agents.
* Serious nonmalignant disease.
* Subjects who are currently receiving any other investigational agent.
* Inadequate renal and liver functions and bone marrow reserve.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
* Adult patients with histologically confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.
* Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.
* Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.
* Karnofsky performance status \>/= 70%.
Exclusion criteria:
* Significant cardiac disease.
* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
* Pregnant or nursing women.
* Treatment with radiation therapy or investigational therapy within 4 weeks prior to Day 1. Had received chemotherapy prior to study entry equivalent to 3 to 5 half-lives of that chemotherapy agent or 4 weeks prior to study entry (whichever is shorter) with resolution of any side effects from that previous therapy (6 weeks for nitrosoureas or Mitomycin C.)
* Subjects with known central nervous system (CNS) metastases, either previously treated or current.
* Disease-free and off therapy for any other cancer within 5 years, except for adequately treated basal cell or squamous cell skin cancer or cervical intraepithelial neoplasia (CIN).
* Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1. o Had minor surgery (superficial incisions unlikely to obscure bleeding or infections) within 2 weeks prior to Day 1.
* Potentially life-threatening disease (hypercalcemia, spinal cord compression) whose disease may progress acutely during therapy.
* Unwilling or unable to comply with procedures required in this protocol.
* Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
* Susceptibility to histamine release.
* Chronic treatment with corticosteroids.
* Baseline QTc exceeding 450 msec (by Bazett's formula) and/or patients receiving class 1A or class III antiarrythmic agents.
* Serious nonmalignant disease.
* Subjects who are currently receiving any other investigational agent.
* Inadequate renal and liver functions and bone marrow reserve.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Inclusion Criteria
Inclusion criteria:
* Adult patients with histologically confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.
* Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.
* Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.
* Karnofsky performance status \>/= 70%.
* Adult patients with histologically confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.
* Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.
* Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.
* Karnofsky performance status \>/= 70%.
Gender
Female
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Estimated
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT01485848
Org Class
Industry
Org Full Name
Esperance Pharmaceuticals Inc
Org Study Id
ACT12601
Overall Status
Completed
Phases
Phase 2
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Primary Outcomes
Outcome Measure
Number of patients with dose limiting toxicities (DLTs) at different doses
Outcome Time Frame
Up to 30 weeks
Outcome Measure
Overall Response Rate (ORR)
Outcome Time Frame
Up to 30 weeks
Secondary Ids
Secondary Id
U1111-1124-2062
Secondary Outcomes
Outcome Time Frame
Up to 18 months
Outcome Measure
Time to Progression (TTP) - Time
Outcome Time Frame
Up to 18 months
Outcome Measure
Progression-free Survival - Time
Outcome Time Frame
Up to 18 months
Outcome Measure
Overall Survival (OS) - Time
Outcome Time Frame
Up to 18 months
Outcome Measure
Duration of Response - Time
Outcome Time Frame
Up to 18 months
Outcome Measure
Number of Participants with Adverse Events
Start Date
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Mark Einstein
Investigator Email
meinstei@montefiore.org
Investigator Phone